Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee.
New anticancer treatments (new therapeutic strategies or new compounds) require careful development in which cancer clinical trials are an essential element. Two scientific committees, namely the New Treatment Committee and the Protocol Review Committee, ensure the review of all EORTC protocols with respect to the interest and originality, methodology, feasibility and relevance within the EORTC framework. Both Committees are involved early in the evaluation of the new concept proposal and follow all aspects (methodology, administrative, regulatory) of the protocol development process. Throughout its 25 years of existence, the Protocol Review Committee has streamlined drug and protocol evaluations and has developed standard operating procedures to handle those reviews in a very efficient and fast manner. Since 1997, the New Treatment Committee has contributed to strengthening the EORTC during the development process with the aim of ensuring an optimal flow of information on new drugs between laboratory and clinical research divisions.
Lardot
C
C
EORTC Data Center, Avenue E. Mounier 83, bte 11, B- 1200, Brussels, Belgium. ntc-prc@eortc.be
Steward
W
W
Van Glabbeke
M
M
Armand
J-P
JP
D002985:Clinical Protocols / Q000592:standards*; D002986:Clinical Trials as Topic / Q000592:standards*; D005060:Europe; D006801:Humans; D007390:International Agencies / Q000458:organization & administration*; D008495:Medical Oncology / Q000458:organization & administration*; D009369:Neoplasms / Q000628:therapy*; D011367:Professional Staff Committees / Q000458:organization & administration*; D012106:Research / Q000592:standards